Stanislas VEILLET – PhD, – Chairman – CEO
Stanislas Veillet created Biophytis in September 2006. He previously held a number of positions in the fields of medical research, nutrition and functional foods, in particular with Danone, Pharmacia-Monsanto and Cargill. Stanislas has a doctorate in genetics, graduated in engineering from AgroParisTech and has authored a dozen patents.
Pr. René LAFONT – Chief Scientific Officer
Co-founder of the company with Stanislas Veillet, René Lafont is a biochemist (Ecole Normale Supérieure), Professor Emeritus at Sorbonne Université (formerly University Pierre et Marie Curie) and former Dean of the Department of Life Sciences. He has authored over 170 scientific publications and a dozen patents, he is also notably a Chevalier de l’Ordre des Palmes Académiques and a Laureate of the Karlson Foundation (Germany).
Samuel Agus has served as our Chief Medical Officer since July 2018. From April 2017 to June 2018 he served as Vice President, Chief Medical Officer of Hansa Medical AB (Publ), a biotechnology company. Prior to that, he served at various leadership positions in clinical development and medical affairs, in several pharmaceutical companies, such as Teva Pharmaceuticals Industries, Solvay Pharmaceuticals, Abbott, Shire and H. Lundbeck A/S. Dr. Agus holds a doctorate in Medicine from The Hebrew University of Jerusalem. He is a board-certified neurologist (from Israel) and has had academic training in biostatistics and bioinformatics.
DANIEL SCHNEIDERMAN – CHIEF FINANCIAL OFFICER
Daniel Schneiderman served as Vice President of Finance and Controller of MetaStat, Inc., a Boston-based precision medicine company focused on developing novel anti-metastatic medications for patients with aggressive cancer. Prior to joining MetaStat in 2012, Mr. Schneiderman was Vice President of Investment Banking for Burnham Hill Partners where he worked from 2004. Mr. Schneiderman began his investment banking career at H.C. Wainwright & Co., Inc. as an Analyst. Mr. Schneiderman holds a Bachelor’s Degree in Economics from Tulane University.
Waly DIOH – PhD – VP Clinical Development
With a doctorate in phytopathology (Paris XI), Waly Dioh spent most of his career with R&D teams in Monsanto, initially in France to set up a genotyping platform and then in the United States (Saint Louis – Missouri) where he ran a regulatory affairs team for the development of biotechnology products. He joined Biophytis at the inception and manages current clinical trials.
PhD in Pharmacology (Paris V University), Dr. Dilda has more than 20 years of experience in pharmaceutical research, in both academic and industrial settings (Mayoli Spindler Laboratories). Before joining Biophytis in December 2015, he was Senior Research Fellow at the Lowy Cancer Research Center at the University of New South Wales (UNSW) in Sydney, Australia, where he was responsible for advancing several cancer therapeutics.
Philippe has a doctorate in Pharmacy (Paris XI University) completed by an Executive‐MBA from ESSEC. He made his career within the pharmaceutical group Lavipharm before joining Opodex Industrie and more recently, Novagali Pharma (Santen group). He joined Biophytis in July 2015 to manage the projects, the regulatory studies and production of the company’s candidates.
Doctor of Medicine (Ludwig-Maximilians-Universität, Munich), PhD in allergology, and an MBA graduate from INSEAD, Manfred Horst spent more than 25 years in the pharmaceutical industry holding multiple strategic positions at Ciba-Geigy/Novartis and serving as CEO of Mercur Value Health Gesundheitspartner (Allianz Group). Prior to joining Biophytis, Manfred Horst was Business Development Director Europe at MSD (Merck & Co.) from 2004 to 2016, where he contributed to numerous licensing agreements.